158 related articles for article (PubMed ID: 10560958)
1. Papillary thyroid carcinoma metastatic to the pituitary gland.
Masiukiewicz US; Nakchbandi IA; Stewart AF; Inzucchi SE
Thyroid; 1999 Oct; 9(10):1023-7. PubMed ID: 10560958
[TBL] [Abstract][Full Text] [Related]
2. Follicular thyroid carcinoma with metastases to the pituitary causing pituitary insufficiency.
Vianello F; Mazzarotto R; Taccaliti A; Lora O; Basso M; Servodio O; Mian C; Sotti G
Thyroid; 2011 Aug; 21(8):921-5. PubMed ID: 21595558
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic accuracy of 131I scanning with recombinant human thyrotropin versus thyroid hormone withdrawal in a patient with metastatic thyroid carcinoma and hypopituitarism.
Ringel MD; Ladenson PW
J Clin Endocrinol Metab; 1996 May; 81(5):1724-5. PubMed ID: 8626823
[TBL] [Abstract][Full Text] [Related]
4. Isolated thyrotropin deficiency secondary to primary empty sella in a patient with differentiated thyroid carcinoma: an indication for recombinant thyrotropin.
Colleran KM; Burge MR
Thyroid; 1999 Dec; 9(12):1249-52. PubMed ID: 10646666
[TBL] [Abstract][Full Text] [Related]
5. Treatment of scan-negative, thyroglobulin-positive metastatic thyroid cancer using radioiodine 131I and recombinant human thyroid stimulating hormone.
Rudavsky AZ; Freeman LM
J Clin Endocrinol Metab; 1997 Jan; 82(1):11-4. PubMed ID: 8989223
[No Abstract] [Full Text] [Related]
6. Symptomatic hyponatremia in association with a low-iodine diet and levothyroxine withdrawal prior to I131 in patients with metastatic thyroid carcinoma.
Shakir MK; Krook LS; Schraml FV; Hays JH; Clyde PW
Thyroid; 2008 Jul; 18(7):787-92. PubMed ID: 18631009
[TBL] [Abstract][Full Text] [Related]
7. Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer: effectiveness for postsurgical remnants ablation and possible role of iodine content in L-thyroxine in the outcome of ablation.
Barbaro D; Boni G; Meucci G; Simi U; Lapi P; Orsini P; Pasquini C; Piazza F; Caciagli M; Mariani G
J Clin Endocrinol Metab; 2003 Sep; 88(9):4110-5. PubMed ID: 12970272
[TBL] [Abstract][Full Text] [Related]
8. Recombinant human thyrotropin in thyroid cancer and hypopituitarism due to sella metastasis.
Risse JH; Grünwald F; Bender H; Schüller H; Van Roost D; Biersack HJ
Thyroid; 1999 Dec; 9(12):1253-6. PubMed ID: 10646667
[TBL] [Abstract][Full Text] [Related]
9. Failure of TSH rise prior to radio-iodine therapy for thyroid cancer: implications for treatment.
Nutting C; Hyer S; Vini L; Harmer C
Clin Oncol (R Coll Radiol); 1999; 11(4):269-71. PubMed ID: 10473725
[TBL] [Abstract][Full Text] [Related]
10. Improving postoperative recurrence rates for carcinoma of the thyroid gland.
McHenry C; Jarosz H; Lawrence AM; Paloyan E
Surg Gynecol Obstet; 1989 Nov; 169(5):429-34. PubMed ID: 2814754
[TBL] [Abstract][Full Text] [Related]
11. Papillary carcinoma of thyroid metastatic to the pituitary gland.
Bell CD; Kovacs K; Horvath E; Smythe H; Asa S
Arch Pathol Lab Med; 2001 Jul; 125(7):935-8. PubMed ID: 11419981
[TBL] [Abstract][Full Text] [Related]
12. Renal metastases from papillary thyroid carcinoma.
Sardi A; Agnone CM; Pellegrini A
J La State Med Soc; 1992 Sep; 144(9):416-20. PubMed ID: 1402321
[TBL] [Abstract][Full Text] [Related]
13. Recombinant human thyrotropin for the diagnosis and treatment of a highly functional metastatic struma ovarii.
Rotman-Pikielny P; Reynolds JC; Barker WC; Yen PM; Skarulis MC; Sarlis NJ
J Clin Endocrinol Metab; 2000 Jan; 85(1):237-44. PubMed ID: 10634393
[TBL] [Abstract][Full Text] [Related]
14. Chromosome translocation frequency after radioiodine thyroid remnant ablation: a comparison between recombinant human thyrotropin stimulation and prolonged levothyroxine withdrawal.
Frigo A; Dardano A; Danese E; Davì MV; Moghetti P; Colato C; Francia G; Bernardi F; Traino C; Monzani F; Ferdeghini M
J Clin Endocrinol Metab; 2009 Sep; 94(9):3472-6. PubMed ID: 19509107
[TBL] [Abstract][Full Text] [Related]
15. Iodine biokinetics and radioiodine exposure after recombinant human thyrotropin-assisted remnant ablation in comparison with thyroid hormone withdrawal.
Taïeb D; Sebag F; Farman-Ara B; Portal T; Baumstarck-Barrau K; Fortanier C; Bourrelly M; Mancini J; De Micco C; Auquier P; Conte-Devolx B; Henry JF; Mundler O
J Clin Endocrinol Metab; 2010 Jul; 95(7):3283-90. PubMed ID: 20392868
[TBL] [Abstract][Full Text] [Related]
16. Ablation of thyroid residues with 30 mCi (131)I: a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal.
Pacini F; Molinaro E; Castagna MG; Lippi F; Ceccarelli C; Agate L; Elisei R; Pinchera A
J Clin Endocrinol Metab; 2002 Sep; 87(9):4063-8. PubMed ID: 12213846
[TBL] [Abstract][Full Text] [Related]
17. rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review.
Luster M; Lippi F; Jarzab B; Perros P; Lassmann M; Reiners C; Pacini F
Endocr Relat Cancer; 2005 Mar; 12(1):49-64. PubMed ID: 15788638
[TBL] [Abstract][Full Text] [Related]
18. Cystic ovarian metastasis from papillary thyroid carcinoma: a case report.
Logani S; Baloch ZW; Snyder PJ; Weinstein R; LiVolsi VA
Thyroid; 2001 Nov; 11(11):1073-5. PubMed ID: 11762718
[TBL] [Abstract][Full Text] [Related]
19. Recombinant human thyroid-stimulating hormone (rhTSH) in the radioablation of well-differentiated thyroid cancer: preliminary therapeutic experience.
Perros P
J Endocrinol Invest; 1999; 22(11 Suppl):30-4. PubMed ID: 10727003
[TBL] [Abstract][Full Text] [Related]
20. Patients with differentiated thyroid cancer who underwent radioiodine thyroid remnant ablation with low-activity ¹³¹I after either recombinant human TSH or thyroid hormone therapy withdrawal showed the same outcome after a 10-year follow-up.
Molinaro E; Giani C; Agate L; Biagini A; Pieruzzi L; Bianchi F; Brozzi F; Ceccarelli C; Viola D; Piaggi P; Vitti P; Pacini F; Elisei R
J Clin Endocrinol Metab; 2013 Jul; 98(7):2693-700. PubMed ID: 23626005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
